C4 Therapeutics, Inc.
CCCC
$2.61
-$0.20-7.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 73.76% | -10.71% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 73.76% | -10.71% | |||
| Cost of Revenue | -0.79% | -3.23% | |||
| Gross Profit | 25.21% | 0.50% | |||
| SG&A Expenses | 1.75% | -6.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.16% | -3.95% | |||
| Operating Income | 16.92% | 2.27% | |||
| Income Before Tax | -23.62% | 1.15% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.62% | 1.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.62% | 1.15% | |||
| EBIT | 16.92% | 2.27% | |||
| EBITDA | 16.74% | 2.86% | |||
| EPS Basic | -20.99% | 1.40% | |||
| Normalized Basic EPS | 23.40% | -3.75% | |||
| EPS Diluted | -20.99% | 1.40% | |||
| Normalized Diluted EPS | 23.40% | -3.75% | |||
| Average Basic Shares Outstanding | 2.19% | 0.24% | |||
| Average Diluted Shares Outstanding | 2.19% | 0.24% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||